Avecia acquires Hybridon's DNA business

Hybridon (HYBN) sold its DNA manufacturing business to Avecia (Manchester, U.K.) for $15 million. The funds will allow HYBN to continue Phase II trials of its GEM 231 antisense compound in solid tumor...